FTC approves Amneal’s $1.45bn acquisition of Impax

The US Federal Trade Commission (FTC) has issued a final approval of Amneal’s $1.45 billion acquisition of Impax.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Impax to divest 10 products amid acquisition by Amneal

30 April 2018 The Federal Trade Commission is requiring Impax to divest rights and assets for ten products, as part of a settlement resolving charges that Amneal’s $1.45 billion acquisition would be anti-competitive.

Americas

Amneal and Impax merge to become ‘fifth largest’ generics company

19 October 2017 Amneal Pharmaceuticals and Impax Laboratories have agreed to merge, in a deal the companies say will create the fifth largest generics drugs business in the US.

Americas

FTC hits Amneal, Impax and Endo with antitrust suit

28 January 2021 The US Federal Trade Commission is suing Endo Pharmaceuticals, Impax Laboratories, and Impax’s owner Amneal Pharmaceuticals, alleging that they were party to a 2017 agreement that violated antitrust law.

More on this story

Americas

Impax to divest 10 products amid acquisition by Amneal

Americas

Amneal and Impax merge to become ‘fifth largest’ generics company

19 October 2017 Amneal Pharmaceuticals and Impax Laboratories have agreed to merge, in a deal the companies say will create the fifth largest generics drugs business in the US.

Americas

FTC hits Amneal, Impax and Endo with antitrust suit

More on this story

Americas

Impax to divest 10 products amid acquisition by Amneal

Americas

Amneal and Impax merge to become ‘fifth largest’ generics company

19 October 2017 Amneal Pharmaceuticals and Impax Laboratories have agreed to merge, in a deal the companies say will create the fifth largest generics drugs business in the US.

Americas

FTC hits Amneal, Impax and Endo with antitrust suit